About GenEdit
GenEdit (now rebranded as BreezeBio) is a biotechnology company that develops genetic medicines using its proprietary NanoGalaxy® platform — a non-viral, non-lipid polymer nanoparticle delivery system. The platform enables targeted, tissue-selective delivery of CRISPR, mRNA, DNA, and RNP payloads, serving pharmaceutical partners and supporting an internal pipeline targeting diseases such as autoimmune disorders and neuromuscular conditions.
Company details
Funding
Total raised
$93.5M
Last stage
Series A
Investors
Founders
Kunwoo Lee
PhD scientist and former postdoc in Jennifer Doudna's UC Berkeley lab. Co-founded GenEdit in 2016 to develop polymer nanoparticle delivery systems for genetic medicines.
LinkedIn
Hyo Min Park
PhD scientist and former graduate student of Niren Murthy at UC Berkeley. Co-founded GenEdit in 2016.
LinkedIn
Niren Murthy
Professor of Bioengineering at UC Berkeley. Co-founded GenEdit in 2016 along with his former graduate students Kunwoo Lee and Hyo Min Park.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.